Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324602 | 0.88 | RXFP1 (0.52) | KDM4EALDH1A1LMNASMN1; SMN2RXFP1 | |
| SCHEMBL222446 | 0.86 | RXFP1 (0.55) | KDM4ELMNASMN1; SMN2RXFP1BRD9 | |
| SCHEMBL29702265 | 0.86 | RXFP1 (0.55) | KDM4ELMNASMN1; SMN2RXFP1BRD9 | |
| SCHEMBL3248129 | 0.85 | NPC1 (0.54) | KDM4EALDH1A1LMNASMN1; SMN2RXFP1 | |
| SCHEMBL8652549 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1LMNASMN1; SMN2CASR | |
| SCHEMBL6183442 | 0.84 | PDK1 (0.59) | LMNARXFP1HPGDMAPK1BRD9 | |
| SCHEMBL14877164 | 0.84 | RXFP1 (0.48) | KDM4ELMNARXFP1HSD17B10BRD9 | |
| SCHEMBL29324603 | 0.83 | RXFP1 (0.46) | KDM4EALDH1A1LMNASMN1; SMN2RXFP1 | |
| SCHEMBL7607973 | 0.82 | CASR (0.52) | ALDH1A1LMNASMN1; SMN2RXFP1CASR | |
| SCHEMBL8651106 | 0.81 | ATR (0.47) | KDM4EALDH1A1LMNARXFP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2705036-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2705035-A1 | TRICYCLIC PYRAZOLE SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012154678-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154679-A1 | TRICYCLIC PYRAZOLE SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2006125293-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2006-11-30 | — | — | WO | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | KDM4E 3106/4885ALDH1A1 287/4885LMNA 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.